IPP Bureau
AptarGroup reported 2021 sales at US $3.23 billion
By IPP Bureau - February 18, 2022
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
LEO Pharma appoints Brian Hilberdink President of LEO Pharma, US
By IPP Bureau - February 18, 2022
Brian joins LEO Pharma from Novo Nordisk, U.S. where he served as Senior Vice President of Sales.
Moderna’s Covid-19 vaccine approved in Australia for children (6-11 years)
By IPP Bureau - February 17, 2022
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
IPP to organize e-conference on 'Indian Pharma Industry: Developing a conducive ecosystem' on Feb 18
By IPP Bureau - February 17, 2022
The speakers for the e-conference are: Dr. Mukund Chorgade, President/CSO, THINQ Pharma; Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Jayaseelan J., National Vice President (Industry Division), Indian Pharmaceutical Association; Spandan Mishra who is Director- Sales, Customer Service & Logistics for Evonik India, Nepal & Sri Lanka region; Dr. Kommu Nagaiah, Chief Scientist & Head, CSIR-IICT; Govind K. Jaju, Partner, Suingora Consulting; nd Pravin Prashant, Executive Editor, Indian Pharma Post & Editor, Indian Chemical News.
Center for Breakthrough Medicines launches analytical testing
By IPP Bureau - February 17, 2022
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Kato wins USFDA approval for studies in retinal disorder
By IPP Bureau - February 17, 2022
Resolv ER may remedy leading causes of blindness in adults
Jubilant Ingrevia commissions Diketene derivatives facility
By IPP Bureau - February 17, 2022
The commissioned facility has a capacity of 7,000 TPA to produce various Esters (Mono Methyl Acetoacetamide, Methyl Acetoacetate, Ethyl Acetoacetate, and Ter-Butyl Acetoacetate)
Rajiv Gupta to retire as chairman of Avantor
By IPP Bureau - February 17, 2022
Gupta to retire at the end of his current term on May 12, 2022, after more than a decade of service, during which time Avantor has transformed into a global life sciences leader
Swissmedic approves BeiGene's Brukinsa
By IPP Bureau - February 17, 2022
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Pebble engages MD Anderson to evaluate multi-cannabinoid formulations in ovarian cancer
By IPP Bureau - February 17, 2022
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Asahi Kasei to build new filter assembly plant in Japan
By IPP Bureau - February 17, 2022
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
PerkinElmer’s SIRION Biotech and CRG to develop diabetes gene therapy
By IPP Bureau - February 17, 2022
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
USFDA approves Lupin’s Supplemental New Drug Application for Solosec
By IPP Bureau - February 17, 2022
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Centauri Therapeutics closes £ 24 million Series A investment round
By IPP Bureau - February 17, 2022
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
USFDA accepts for Priority Review Bristol Myers Squibb’s Supplemental BLA for Breyanzi
By IPP Bureau - February 17, 2022
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
